Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
When first starting Farxiga (dapagliflozin), the most common side effects include increased urination, genital yeast infections, urinary tract infections, mild dehydration with dizziness or lightheadedness, and back or joint discomfort, and there are several important factors to consider, as explained below. Many people notice these effects within the first days to weeks as the medication flushes extra sugar through the urine, and symptoms often ease as the body adjusts. Rare but serious reactions, including ketoacidosis with normal blood sugar, severe genital infections, and low blood sugar when combined with insulin or sulfonylureas, are detailed below and deserve close attention.
If you are unsure whether what you feel is a normal adjustment or a warning sign, a few minutes of clarity now can spare you days of worry and possibly an avoidable emergency. Take a free, instant, online symptom check to see how your symptoms line up with common Farxiga effects, learn which ones warrant same-day medical care, and walk into your next appointment with clear, specific questions.
Last reviewed for medical accuracy: 09/17/2026
Farxiga (dapagliflozin) is a prescription medication in the SGLT2 inhibitor class used to improve blood sugar control in adults with type 2 diabetes. It works by helping your kidneys remove excess glucose through urine. Like any medicine, Farxiga can cause side effects—especially when you first start taking it. Below is an overview of the most common side effects, why they happen, how to manage them, and when to seek medical help.
Introduction
When you begin Farxiga, your body adapts to increased glucose removal and fluid shifts. Many side effects are mild, temporary, and manageable with simple measures. Awareness and early action can help you stay on track with treatment and minimize discomfort.
Why These Side Effects Occur When You First Start
• Adaptation phase: Your body needs time to adjust to changes in kidney glucose handling and fluid balance.
• Peak incidence: Many side effects appear within the first 2–4 weeks.
• Temporary nature: Most mild side effects improve as your body adapts.
Tips for a Smoother Start
• Follow dosing instructions: Take Farxiga exactly as prescribed, usually once daily in the morning with or without food.
• Stay hydrated: Aim for 6–8 cups of water (or approved fluids) daily unless otherwise instructed.
• Monitor: Keep a log of side effects, fluid intake, and any signs of infection.
• Communicate: Share your log with your doctor or diabetes educator at follow-up visits.
• Lifestyle: Balanced diet, regular exercise, and blood sugar monitoring can reduce side effect risk.
When to Call Your Doctor
Even though most side effects are mild, some require prompt medical attention. Contact your healthcare provider if you experience:
• Signs of serious dehydration: fainting, extreme thirst, very dry mouth or skin
• Symptoms of diabetic ketoacidosis: persistent nausea, vomiting, severe abdominal pain, rapid breathing, confusion
• Severe urinary or genital infection: fever, chills, back or flank pain, blood in urine
• Sudden weakness, irregular heartbeat, or muscle cramps (possible electrolyte imbalance)
• Any other symptom that feels life-threatening or severe
Next Steps and Resources
• Track your symptoms: Use a notebook or mobile app to record side effects, fluid intake, and blood sugar readings.
• Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance on mild to moderate issues.
• Review your medication list: Let your doctor know about all prescription and over-the-counter medicines, vitamins, and supplements you take.
Conclusion
Starting Farxiga can bring meaningful improvements in blood sugar control and cardiovascular health. By knowing the most common side effects—such as increased urination, thirst, genital infections, and dehydration—you’ll be prepared to manage them and stay on course. Most side effects are mild and resolve as your body adjusts, but always speak to a doctor about anything that could be life-threatening or serious. With good hydration, hygiene, and open communication with your healthcare team, you can make your Farxiga experience as smooth and safe as possible.
(References)
* Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. PMID: 28105986; PMCID: PMC5292646.
* Iqbal I, Hamid M, Khan MAA, Kainat A, Tariq S. Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis. Cureus. 2019 Nov 7;11(11):e6089. doi: 10.7759/cureus.6089. Epub 2019 Nov 7. PMID: 31857921; PMCID: PMC6897349.
* Comparison chart: SGLT2 inhibitors. Med Lett Drugs Ther. 2020 Nov 16;62(1611):e2-e4. Epub 2020 Nov 16. PMID: 33429417.
* Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, Drożdż J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderäng U, Claggett BL, Solomon SD, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 Oct 18;146(16):1210-1224. doi: 10.1161/CIRCULATIONAHA.122.061754. Epub 2022 Aug 27. PMID: 36029465; PMCID: PMC9815819.
* Drugs for type 2 diabetes. Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-184. PMID: 36384763.
* Mårup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin Kidney J. 2024 Jan;17(1):sfad249. doi: 10.1093/ckj/sfad249. Epub 2023 Sep 26. PMID: 38186886; PMCID: PMC10768792.
* Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fernández-Fernández B, Forst T, Frias JP, Gavin JR 3rd, Giorgino F, Groop PH, Heerspink HJL, Herzig S, Hummel M, Huntley G, Ibrahim M, Itzhak B, Jacob S, Ji L, Kosiborod M, Lalic N, Macieira S, Malik RA, Mankovsky B, Marx N, Mathieu C, Müller TD, Ray K, Rodbard HW, Rossing P, Rydén L, Schumm-Draeger PM, Schwarz P, Škrha J, Snoek F, Tacke F, Taylor B, Jeppesen BT, Tesfaye S, Topsever P, Vilsbøll T, Yu X, Standl E. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024 Mar 19;23(1):104. doi: 10.1186/s12933-024-02180-8. Epub 2024 Mar 19. PMID: 38504284; PMCID: PMC10953147.
* Lava SAG, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review. Paediatr Drugs. 2024 May;26(3):229-243. doi: 10.1007/s40272-024-00623-z. Epub 2024 Apr 18. PMID: 38635113.
* Shi Y, Zhang J, Xin X, Liu L, Wu Y, Cheng Y, Zhang L, Su H, Zhao Y. Effects of dapagliflozin on podocyte damage and oxidative stress in patients with diabetic nephropathy. Diabetol Metab Syndr. 2025 Aug 9;17(1):323. doi: 10.1186/s13098-025-01886-3. Epub 2025 Aug 9. PMID: 40783743; PMCID: PMC12335153.
* Lloyd A, Austin-Muttitt K, Mullins JGL. Computational structural studies of SGLT2-related polypharmacy. PLoS One. 2025;20(10):e0334656. doi: 10.1371/journal.pone.0334656. Epub 2025 Oct 17. PMID: 41105702; PMCID: PMC12533862.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.